scholarly journals Anaesthetic antacids: a review of its pharmacological properties and therapeutic efficacy

2018 ◽  
Vol 6 (2) ◽  
pp. 383 ◽  
Author(s):  
Rajendra Kumar Parakh ◽  
Neelakanth S. Patil
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Expert Panel ◽  
Acid Neutralizing Capacity ◽  
Management Algorithm ◽  
Neutralizing Capacity ◽  
H2 Receptor Blockers ◽  
Receptor Blockers ◽  
Reversible Loss

Anaesthetic antacids, combination of antacids (Aluminium hydroxide, Magnesium hydroxide) with an anaesthetic (oxethazaine), is becoming a choice of physicians and is re-emerging across all types of GI disorders (esophagitis, peptic ulcer, duodenal ulcer, heartburn, gastritis, functional dyspepsia), despite the discovery of potent and efficacious acid suppressants like H2 receptor blockers and proton pump inhibitors (PPIs). The reason being that anaesthetic antacids increase the gastric pH and provide relief from pain for a longer period of duration at considerably a lower dosage. Furthermore, it significantly increases the duration between the time of medication and the peak pH as compared to antacid alone. Oxethazaine, an anaesthetic component, produces a reversible loss of sensation and provides a prompt and prolonged relief of pain, thereby broadening the therapeutic spectrum of antacids. Antacids vary widely in their in vitro acid neutralizing capacity (ANC), which measures the potency. Among marketed brands in India, Digecaine has shown the highest potency with maximum mean ANC value (28.84 mEq). The expert panel has recommended the inclusion of oxethazaine-antacid/alginate-antacid as complementary to the proton pump inhibitors in the management algorithm of gastroesophageal reflux disease. The present review summarizes the pharmacokinetic and pharmacodynamic of different components of anaesthetic antacids and its clinical use across different gastrointestinal indications, for generalists and specialists, based on existing evidences.

scholarly journals LONG-TERM SAFETY OF CONCOMITANT USE OF PROTON PUMP INHIBITORS AND H2 RECEPTOR BLOCKERS WITH THIENOPYRIDINES IN THE SETTING OF CORONARY STENTING

2014 ◽  
Vol 63 (12) ◽  
pp. A226
Author(s):  
Matthew Butler ◽  
Christopher Buckley ◽  
Calvin Madrigal ◽  
Arun Raghav Mahankali Sridhar ◽  
Buddhadeb Dawn
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Coronary Stenting ◽  
H2 Receptor ◽  
H2 Receptor Blockers ◽  
Receptor Blockers

Evaluation of Hemidesmus indicus root as an antacid by In vitro

2016 ◽  
Vol 5 (04) ◽  
pp. 4524
Author(s):  
Abdullah Shaikh Farooque ◽  
Md. Azharuddin Ismail Atar*
Keyword(s):  
Skin Diseases ◽  
Care Delivery ◽  
Health Care Delivery System ◽  
Acid Neutralizing Capacity ◽  
Standard Drug ◽  
Hemidesmus Indicus ◽  
Neutralizing Capacity ◽  
Loss Of Appetite ◽  
Powdered Drug

Medicinal plants are being widely used, either as single drug or in combination in health care delivery system. Indian Sarsaparilla, Hemidesmus indicus (Family: Asclepiadaceae) is a commonly known Indian Medicinal Plant, which is widely recognized in traditional systems of Medicine. It contains various phytoconstituents belonging to the category glycosides, flavonoids, tannins, sterols and volatile oils. It has been reported as useful in biliousness, blood diseases, dysentery, diarrhea, respiratory disorders, skin diseases, syphilis, fever, leprosy, leucoderma, leucorrhoea, itching, bronchitis, asthma, eye diseases, epileptic fits in children, kidney and urinary disorders, loss of appetite, burning sensation, dyspepsia, nutritional disorders, ulcer and rheumatism. Several studies are being carried towards its activities like analgesic, anti-inflammatory, antiulcer, hepatoprotective, antioxidant and helicobactericidal properties. In our study we have evaluated antacid activity of sariva (Anantmool) by using In-Vitro method, i.e. ANC (Acid Neutralizing Capacity). This evaluation was done by comparing the ANC of sariva macerated & powdered drug with water as blank & standard drug i.e. NaHCO3. Based on this In-Vitro experiment, we can conclude that, the macerated & powdered drug of sariva (Anantmool) evaluated in this study, varied in potency as measured in terms of their ANC. These results having ** i.e. P < 0.01 & Passed the normality test. However, the present study being in-vitro, the effects of antacid may vary In-Vitro; individual variations also contribute to the ultimate effectiveness of as antacid.        

scholarly journals In-vitro antiulcer activities of petal extract of Crocus sativus var. cashmerianus

2020 ◽  
pp. 6-8
Author(s):  
Vijender Kumar ◽  
Poonam Verma ◽  
Amarjit Kaur ◽  
Baljinder Singh
Keyword(s):  
Crocus Sativus ◽  
Acid Neutralizing Capacity ◽  
Inhibition Activity ◽  
Similar Dose ◽  
Neutralizing Capacity ◽  
Activity Method ◽  
Atpase Inhibition ◽  
Acid Neutralize ◽  
Capacity Method

Medicinal plants have been known for millennia as a rich source of traditional therapeutic agents for the prevention of diseases and ailments. The aim of the present study was performed to evaluate the antiulcer activities of hydro-alcoholic extracts of petals of Crocus sativus var. Cashmerianus by in-vitro methods viz. acid neutralizing capacity and H+/K+ - ATPase inhibition activity. In acid neutralizing capacity method, the petals extract significantly reduced acidity to 6.10 at a concentration of 1000 mg/ml as compared to 11.90 with standard 500 mg/ml of Aluminium hydroxide + Magnesium hydroxide combination. However, H+/K+ - ATPase inhibition activity method, petals extract showed maximum percentage inhibition of 70.31 % at the concentration 400µg/ml as compared to 73.82 % with a similar dose of standard Omeprazole. The IC 50 value of petals extract of C. sativus var. cashmerianus is shown 100 µg/ml in comparison with standard omeprazole of 82.5 µg/ml. The study reveals that the petals extract of C. sativus var. cashmerianus may contain compounds possessing acid neutralize and enzyme inhibition activities, thus it can be used as an alternative medicine for gastrointestinal disorders.

scholarly journals RANITIDINE CONTROLLED RELEASE ANTI-REFLUX SUSPENSION FOR GASTRO-OESOPHAGEAL REFLUX DISEASE AND IT’S IN VITRO EVALUATION

2019 ◽  
Vol 11 (1) ◽  
pp. 74
Author(s):  
Sangmesh R. Torne ◽  
Sheela A. ◽  
Sarada N. C.
Keyword(s):  
Controlled Release ◽  
Reflux Disease ◽  
Oesophageal Reflux ◽  
Gelling Agent ◽  
Acid Neutralizing Capacity ◽  
Simulated Gastric Fluid ◽  
In Vitro Evaluation ◽  
Oesophageal Reflux Disease ◽  
Neutralizing Capacity

Objective: The aim of this work was to develop triple action controlled release anti-reflux suspension of ranitidine and its in-vitro evaluation of anti-reflux and controlled release properties.Methods: The formulation was optimized using sodium alginate as a gelling agent along with calcium carbonate, sodium bicarbonate, magnesium hydroxide, aluminium hydroxide as alkalizing agents and colloidal microcrystalline cellulose (MCC) as a suspending agent at various concentrations and arrived at an optimized formulation for its best quality attributes. To avoid initial release in water before administration, ranitidine coated MCC sphere was incorporated into powder formulation and subjected to in vitro characteristics like raft strength, acid neutralizing capacity, pH, viscosity and dissolution study. The obtained results were assessed using Minitab 17 statistical software to conclude the study design.Results: Formulation containing 300 mg of ranitidine along with 750 mg alginate has shown better anti-reflux characteristics like raft strength 18±2g, acid neutralizing capacity 17±1 mEq compared to other formulations. This formulation has also shows zero-order controlled release in the simulated gastric fluid (SGF) up to 10 h compared to the formulation without alginate. Further, to this optimized formulation has shown negligible change in the assay of ranitidine even after 3 mo at 40 °C temperature and 75% RH.Conclusion: The developed stable sustained release powder for suspension has the combined therapeutic efficacy as an antacid and anti-reflux drug suitable for the management and treatment of gastro-oesophageal reflux disease (GERD) unlike the existing drugs possessing only reflux resistance action.

Sign in / Sign up

Export Citation Format

Share Document